|
1
|
Kim WJ, Park S and Kim YJ: Biomarkers in
bladder cancer: Present status and perspectives. Biomark Insights.
2:95–105. 2007.PubMed/NCBI
|
|
2
|
Gregg JR, Dahm P and Chang SS:
Guideline-based management of non-muscle invasive bladder cancer.
Indian J Urol. 31:320–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clark P, Agarwal N and Biagioli M: NCCN
clinical practice guideline in oncology: Bladder cancer. Version I.
2013, simpleNCCN.orgJanuary 10–2013
|
|
4
|
Ahn JH, Jung SI, Yim SU, Kim SW, Hwang EC
and Kwon DD: Impact of glycemic control and metformin use on the
recurrence and progression of non-muscle invasive bladder cancer in
patients with diabetes mellitus. J Korean Med Sci. 31:1464–1471.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yun SJ, Kim SK and Kim WJ: How do we
manage high-grade T1 bladder cancer? Conservative or aggressive
therapy? Investig Clin Urol. 57 Suppl 1:S44–S51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Milowsky MI, Rumble RB, Booth CM, Gilligan
T, Eapen LJ, Hauke RJ, Boumansour P and Lee CT: Guideline on
muscle-invasive and metastatic bladder cancer (European Association
of Urology guideline): American society of clinical oncology
clinical practice guideline endorsement. J Clin Oncol.
34:1945–1952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A;
European Association of Urology, : EAU guidelines on
muscle-invasive and metastatic bladder cancer: Summary of the 2013
guidelines. Eur Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Epstein JI, Amin MB, Reuter VR and Mostofi
FK: The World Health Organization/International Society of
Urological Pathology consensus classification of urothelial
(transitional cell) neoplasms of the urinary bladder. Am J Surg
Pathol. 22:1435–1448. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
May M, Brookman-Amissah S, Roigas J,
Hartmann A, Störkel S, Kristiansen G, Gilfrich C, Borchardt R,
Hoschke B, Kaufmann O and Gunia S: Prognostic accuracy of
individual uropathologists in noninvasive urinary bladder
carcinoma: A multicentre study comparing the 1973 and 2004 World
Health Organisation classifications. Eur Urol. 57:850–858. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dyrskjøt L, Zieger K, Real FX, Malats N,
Carrato A, Hurst C, Kotwal S, Knowles M, Malmström PU, de la Torre
M, et al: Gene expression signatures predict outcome in
non-muscle-invasive bladder carcinoma: A multicenter validation
study. Clin Cancer Res. 13:3545–3551. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Rhijn BW, Burger M, Lotan Y, Solsona
E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and
progression of disease in non-muscle-invasive bladder cancer: From
epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van den Bosch S and Witjes JA: Long-term
cancer-specific survival in patients with high-risk,
non-muscle-invasive bladder cancer and tumour progression: A
systematic review. Eur Urol. 60:493–500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sylvester RJ, van der Meijden AP,
Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and
Kurth K: Predicting recurrence and progression in individual
patients with stage Ta T1 bladder cancer using EORTC risk tables: A
combined analysis of 2596 patients from seven EORTC trials. Eur
Urol. 49:466–477. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fernandez-Gomez J, Madero R, Solsona E,
Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa
C, Rodriguez-Molina J, et al: Predicting nonmuscle invasive bladder
cancer recurrence and progression in patients treated with bacillus
Calmette-Guerin: The CUETO scoring model. J Urol. 182:2195–2203.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim WJ and Bae SC: Molecular biomarkers in
urothelial bladder cancer. Cancer Sci. 99:646–652. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kamat AM, Hegarty PK, Gee JR, Clark PE,
Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ,
Lotan Y, et al: ICUD-EAU international consultation on bladder
cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol.
63:4–15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang HW, Yoon HY, Ha YS, Kim WT, Kim YJ,
Yun SJ, Lee SC and Kim WJ: FAM70B as a novel prognostic marker for
cancer progression and cancer-specific death in muscle-invasive
bladder cancer. Korean J Urol. 53:598–606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Netto GJ: Molecular biomarkers in
urothelial carcinoma of the bladder: Are we there yet? Nat Rev
Urol. 9:41–51. 2012. View Article : Google Scholar
|
|
20
|
Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS,
Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, et al: Predictive value
of progression-related gene classifier in primary non-muscle
invasive bladder cancer. Mol Cancer. 9:32010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brausi M, Witjes JA, Lamm D, Persad R,
Palou J, Colombel M, Buckley R, Soloway M, Akaza H and Böhle A: A
review of current guidelines and best practice recommendations for
the management of nonmuscle invasive bladder cancer by the
International Bladder Cancer Group. J Urol. 186:2158–2167. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Greene FL: The American Joint Committee on
Cancer: Updating the strategies in cancer staging. Bull Am Coll
Surg. 87:13–15. 2002.PubMed/NCBI
|
|
23
|
Kirkali Z, Chan T, Manoharan M, Algaba F,
Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM,
et al: Bladder cancer: Epidemiology, staging, and grading and
diagnosis. Urology. 66 6 Suppl 1:S4–S34. 2005. View Article : Google Scholar
|
|
24
|
Jeong P, Ha YS, Cho IC, Yun SJ, Yoo ES,
Kim IY, Choi YH, Moon SK and Kim WJ: Three-gene signature predicts
disease progression of non-muscle invasive bladder cancer. Oncol
Lett. 2:679–684. 2011.PubMed/NCBI
|
